What we know, what we don’t, and how we protect patients.

What matters most

Regenera does not offer cellular therapy as a standard or first-line treatment. Whether a therapy is appropriate — and which one — is a clinical decision made after evaluation.
Not every patient is a candidate for advanced regenerative therapy. When that is the case, we say so.
Eligibility is determined at the medical review — not from a website form or a treatment package.
Mechanism, current evidence, limitations and risks are discussed before consent.

Therapies

How we discuss each therapy

Open each one for what it is, where the evidence stands, and the safety and selection points. These are educational descriptions, not an offer of treatment.

Mesenchymal stem cells

What it is: Living cells used in selected clinical contexts for their signalling and immunomodulatory activity.
Why it may be considered: Considered only after medical evaluation, and only when there is a clinical rationale for the specific situation.
Where the evidence stands: Evidence differs substantially by indication. Any potential benefit is discussed individually and is never presented as guaranteed.
Safety & selection: The source and characterisation of any cellular product, eligibility, and the administration plan are reviewed with the patient as part of the clinical and informed-consent process before any use.

Exosomes

What it is: Cell-derived extracellular vesicles that carry signalling molecules.
Why it may be considered: May be discussed as a supportive biologic modality in selected situations.
Where the evidence stands: The evidence is still developing and should be distinguished from evidence for whole-cell therapies.
Safety & selection: Source, processing, traceability and the limits of current evidence are made clear before any use.

PRP / PRGF

What it is: Preparations made from the patient’s own blood, concentrated for their platelet content.
Why it may be considered: May be considered for selected musculoskeletal or tissue-repair indications.
Where the evidence stands: Evidence and expected benefit depend on the condition, the preparation and the technique.
Safety & selection: A physician determines the indication, preparation and administration.

Supportive therapies

What it is: Adjunctive interventions used within the broader Regenera Method™ (for example ozone therapy, differentiated IV therapy).
Why it may be considered: Used to address selected clinical goals before or alongside other interventions.
Where the evidence stands: These are supportive measures. They are not a substitute for diagnosis or standard medical care.
Safety & selection: Selection depends on medical history, contraindications and physician judgement.

Quality & traceability

Eligibility, quality control & traceability

For any therapy involving a cellular product, the clinical team reviews eligibility, the source and handling of the product, and the available quality-control information with the patient. Where partner laboratories are involved, Regenera documents the applicable processing and traceability information rather than treating “international standards” as a blanket guarantee of safety or effectiveness.

Frequently asked questions

Does a medical review guarantee treatment?

No. The review determines whether a program or an advanced therapy should be considered at all.

Does the RBRI™ diagnose a disease?

No. It is a structured assessment that supports clinical interpretation. It is not a stand-alone diagnostic test.

Are outcomes guaranteed?

No. Expected outcomes and their uncertainty are discussed individually and depend on the indication, patient factors and the intervention.

This page is educational and does not replace individual medical advice. Evidence can vary by therapy and by indication.

Begin with a medical evaluation, not a booking.

The Regenerative Medical Review is the eligibility-gated entry point to every program.

Request Medical Review